Cargando…
T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621564/ http://dx.doi.org/10.1097/01.HS9.0000890800.36906.bb |
| _version_ | 1784821586706038784 |
|---|---|
| author | Timmerman, John Lavie, David Johnson, Nathalie A. Avigdor, Abraham Borchmann, Peter Andreadis, Charalambos Bazargan, Ali Gregory, Gareth Keane, Colm Tzoran, Inna Vucinic, Vladan Zinzani, Pier Luigi Zhang, Hong Pillai, Pallavi Nahar, Akash Herrera, Alex F. |
| author_facet | Timmerman, John Lavie, David Johnson, Nathalie A. Avigdor, Abraham Borchmann, Peter Andreadis, Charalambos Bazargan, Ali Gregory, Gareth Keane, Colm Tzoran, Inna Vucinic, Vladan Zinzani, Pier Luigi Zhang, Hong Pillai, Pallavi Nahar, Akash Herrera, Alex F. |
| author_sort | Timmerman, John |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9621564 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96215642022-11-01 T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment Timmerman, John Lavie, David Johnson, Nathalie A. Avigdor, Abraham Borchmann, Peter Andreadis, Charalambos Bazargan, Ali Gregory, Gareth Keane, Colm Tzoran, Inna Vucinic, Vladan Zinzani, Pier Luigi Zhang, Hong Pillai, Pallavi Nahar, Akash Herrera, Alex F. Hemasphere Immunotherapy Lippincott Williams & Wilkins 2022-10-03 /pmc/articles/PMC9621564/ http://dx.doi.org/10.1097/01.HS9.0000890800.36906.bb Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Immunotherapy Timmerman, John Lavie, David Johnson, Nathalie A. Avigdor, Abraham Borchmann, Peter Andreadis, Charalambos Bazargan, Ali Gregory, Gareth Keane, Colm Tzoran, Inna Vucinic, Vladan Zinzani, Pier Luigi Zhang, Hong Pillai, Pallavi Nahar, Akash Herrera, Alex F. T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment |
| title | T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment |
| title_full | T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment |
| title_fullStr | T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment |
| title_full_unstemmed | T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment |
| title_short | T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment |
| title_sort | t058: safety and dose-expansion study of combination favezelimab (anti–lag-3) plus pembrolizumab in patients with relapsed or refractory classical hodgkin lymphoma refractory to anti–pd-1 treatment |
| topic | Immunotherapy |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621564/ http://dx.doi.org/10.1097/01.HS9.0000890800.36906.bb |
| work_keys_str_mv | AT timmermanjohn t058safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomarefractorytoantipd1treatment AT laviedavid t058safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomarefractorytoantipd1treatment AT johnsonnathaliea t058safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomarefractorytoantipd1treatment AT avigdorabraham t058safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomarefractorytoantipd1treatment AT borchmannpeter t058safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomarefractorytoantipd1treatment AT andreadischaralambos t058safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomarefractorytoantipd1treatment AT bazarganali t058safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomarefractorytoantipd1treatment AT gregorygareth t058safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomarefractorytoantipd1treatment AT keanecolm t058safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomarefractorytoantipd1treatment AT tzoraninna t058safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomarefractorytoantipd1treatment AT vucinicvladan t058safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomarefractorytoantipd1treatment AT zinzanipierluigi t058safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomarefractorytoantipd1treatment AT zhanghong t058safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomarefractorytoantipd1treatment AT pillaipallavi t058safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomarefractorytoantipd1treatment AT naharakash t058safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomarefractorytoantipd1treatment AT herreraalexf t058safetyanddoseexpansionstudyofcombinationfavezelimabantilag3pluspembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomarefractorytoantipd1treatment |